US MOVERS&SHAKERS Apr 22-Apr 26, 2024
Here are the top 10 gainers and losers of the week.
BeiGene (NASDAQ:BGNE) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
BeiGene reports 2023 annual results, with revenue surging 82.13% to 17.423 billion yuan
According to the Zhitong Finance App, BeiGene (688235.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 17.423 billion yuan, a year-on-year increase of 82.13%; net loss attributable to shareholders of listed companies narrowed sharply to 6.716 billion yuan. Baiyueze, a BTK inhibitor independently developed by the company, has been approved for multiple indications in 70 markets including the United States, China, the European Union, the United Kingdom, Canada, Australia, South Korea and Switzerland. It has established an extensive clinical development layout around the world, and has enrolled more than 5,000 subjects in 29 countries and regions. Momoetsusawa
BeiGene Releases “2023 Responsible Business and Sustainability” Report, Announces Global Progress
The 2023 annual report details the company's achievements in sustainability and future plans in Beijing, China; Cambridge, MA; and Basel, Switzerland, April 26, 2024/PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology innovation company, today released the “2023 Responsible Business and Sustainability” report, which highlights the company's strategy, progress made with current goals, and how to achieve more in the future Positive new goals. In the report
百濟神州:2023年度報告
Express News | Beigene : Bernstein Cuts Target Price to $152 From $161
BeiGene (BGNE) Receives a Hold From Bernstein
Global Oncology Innovator BeiGene Highlights New Data Across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.
Evaluating BeiGene: Insights From 6 Financial Analysts
In the last three months, 6 analysts have published ratings on BeiGene (NASDAQ:BGNE), offering a diverse range of perspectives from bullish to bearish.The following table provides a quick overview of
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Is Maintained at Buy by TD Cowen
Express News | TD Cowen Maintains Buy on BeiGene, Raises Price Target to $236
BeiGene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 64.52% TD Cowen $235 → $236 Maintains Buy 04/08/2024 14.53% B of A Securities $179.3 → $164.3 M
Express News | BeiGene Shares Are Trading Higher After the European Commission on Tuesday Approved Tislelizumab for Non-small Cell Lung Cancer Across Three Indications, Including First- and Second-line Use
Sector Update: Health Care Stocks Rise in Afternoon Trading
Health care stocks were advancing Tuesday afternoon, with the NYSE Health Care Index gaining 1.4% and the Health Care Select Sector SPDR Fund (XLV) up 1.3%. The iShares Biotechnology ETF (IBB) rose 1.
EU Regulators Approve BeiGene's Tislelizumab for Lung Cancer
Selected Gelonghui Announcements (Hong Kong Stocks) | Tianqi Lithium (09696.HK) Profit Alert: Expected loss of 3.6 billion to 4.3 billion yuan in the first quarter
[Today's Focus] Tianqi Lithium (09696.HK) Profit Warning: Expected loss of 3.6 billion yuan to 4.3 billion yuan in the first quarter Tianqi Lithium (09696.HK) announcement. The company expects a three-month period ending March 31, 2024. (i) The net loss range attributable to the company's shareholders is RMB 36 million to RMB 43 million (unreviewed), while the net profit attributable to the company's shareholders during the same period last year was RMB 4,875.23 million; (ii) the net loss range after deducting non-recurring profit and loss is RMB 4,875.23 million; (ii) the net loss range after deducting non-recurring profit and loss is in the RMB range 3,600 One million yuan to RMB 4,40
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday.Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply during Tuesday's session following upbeat quarterly result
Express News | BeiGene Shares Are Trading Higher After the European Commission Approved Tislelizumab for Non-small Cell Lung Cancer Across Three Indications, Including First- and Second-line Use
With 42% Ownership of the Shares, BeiGene, Ltd. (NASDAQ:BGNE) Is Heavily Dominated by Institutional Owners
BeiGene (688235.SH): European Commission approves Baizean for first-line and second-line treatment of three non-small cell lung cancer indications
Gelonghui, April 23 | BeiGene (688235.SH) announced recently that the European Commission has granted marketing license to Baizean (tirelizumab injection) and approved it for first-line and second-line treatment of three non-small cell lung cancer (NSCLC) indications: combination paclitaxel and carboplatin or injectable paclitaxel (albumin conjugated type) and carboplatin for use in first-line treatment of adult patients with platinum-containing radiotherapy; combined with chemotherapeutics containing platinum Used for PD-L1 expression ≥ 50% and no epidermis growth factor receptor (EGFR)
No Data